A comparative study of two PODXL antibodies in 840 colorectal cancer patients
| Autor: | Jaana Hagström, Caj Haglund, Harri Mustonen, Tuomas Kaprio, Olle Nilsson, Christian Fermér, Camilla Böckelman |
|---|---|
| Přispěvatelé: | Haartman Institute (-2014), Department of Pathology, Clinicum, Department of Surgery, Research Programs Unit, Translational Cancer Biology (TCB) Research Programme, II kirurgian klinikka |
| Rok vydání: | 2014 |
| Předmět: |
Male
Cancer Research Pathology Cytoplasm Colorectal cancer TUMOR-CELLS Epitope Cohort Studies chemistry.chemical_compound Prostate cancer 0302 clinical medicine Surgical oncology Medicine 0303 health sciences Podocalyxin biology ATLAS Middle Aged PODOCALYXIN-LIKE PROTEIN Prognosis PROSTATE-CANCER 3. Good health Oncology 030220 oncology & carcinogenesis Female Antibody Colorectal Neoplasms Research Article medicine.medical_specialty medicine.drug_class Sialoglycoproteins education Monoclonal antibody BREAST Antibodies Disease-Free Survival SELECTIN LIGAND 03 medical and health sciences POOR-PROGNOSIS Genetics Biomarkers Tumor Humans Allele 030304 developmental biology Aged business.industry Cell Membrane 3126 Surgery anesthesiology intensive care radiology medicine.disease INDEPENDENT FACTOR chemistry Cancer research biology.protein OVEREXPRESSION 3111 Biomedicine business |
| Zdroj: | BMC Cancer |
| ISSN: | 1471-2407 |
| Popis: | Background Podocalyxin (PODXL) is a transmembrane sialomucin, whose aberrant expression and/or allelic variation associates with poor prognosis and unfavourable clinicopathological characteristics in different cancers. Membranous expression of PODXL has been suggested to be an independent marker of poor prognosis in colorectal cancer (CRC), and previously by an in-house monoclonal antibody, we showed that also cytoplasmic overexpression of PODXL predicts poor prognosis. The aim of this study was to compare two PODXL antibodies with different epitopes case-by-case in CRC patients. Methods Of 840 consecutively operated CRC patients from Helsinki University Central Hospital, PODXL expression by polyclonal HPA 2110 antibody was evaluated from 780. Associations of PODXL expression with clinicopathological parameters and the impact of PODXL expression on survival were assessed. Kappa-value was used to assess the comparability of the two antibodies. Results Membranous PODXL expression associated with unfavourable clinicopathological parameters and with higher risk for disease-specific death from CRC within 5 years (unadjusted hazard ratio (HR) = 1.90; 95% confidence interval (CI) (1.32-2.75); adjusted HR = 1.64; 95% CI (1.11-2.43)). The comparability of expressions by the two antibodies was low (kappa =0.219, standard error 0.060, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|